<DOC>
	<DOC>NCT00701545</DOC>
	<brief_summary>As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-center structured data collection of routine management of patients with von Willebrand disease treated with Humate P® ivr in Canada. The surveillance will be non-interventional and non-experimental. During the observation period, the routine medical care of the patient will be documented. It is expected that there will be no difference in the safety and tolerability of Humate-P® ivr compared to Humate-P®</brief_summary>
	<brief_title>A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Male or female patients of any age; Patients who are suffering with von Willebrand disease previously treated with HumateP®; Patients who are able to communicate well with the Investigator and his/her representatives; Patients who are able and agreeing to comply with all study requirements; Patients who have provided written signed and dated informed consent prior to any study procedures being performed. Patients who have received any investigational drug ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>von Willebrand disease</keyword>
	<keyword>VWD, Humate-P®</keyword>
	<keyword>Infusion volume reduced</keyword>
	<keyword>ivr</keyword>
</DOC>